fda statement bpc-157 not approved fda.gov Undercutting HHS Secretary Robert F. Kennedy Jr.'s recent push to expand access to peptides, career scientists determined there isn't adequate evidence to support any of the ones under consideration for production The biggest regulatory moment for
The biggest regulatory moment for peptides in 2026 happens this week. On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee meets to vote on whether BPC 157, TB 500, KPV, MOTS c, DSIP A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! An FDA panel will consider whether to allow compounding pharmacies to manufacture certain peptides. Here's what to know about their safety and efficacy. I just testified at an FDA meeting on whether seven popular peptides should be allowed in compounding. Just last month, FDA medical officers determined that none of the peptides met the agency's BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & BPC 157 Legal Status: FDA Regulations and Compounding
Pay in 4 interest-free payments of $5.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
